delavirdine + nelfinavir + stavudine + didanosine

This drug is a **combination regimen** consisting of four antiretroviral agents: delavirdine, nelfinavir, stavudine, and didanosine. It combines agents from three antiretroviral classes for the treatment of **HIV infection**: - **Delavirdine** is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 reverse transcriptase by noncompetitive binding, thereby preventing the conversion of viral RNA to DNA. - **Nelfinavir** is an HIV-1 protease inhibitor that interferes with the proteolytic cleavage of the HIV gag-pol polyprotein, resulting in the production of immature, noninfectious viral particles. - **Stavudine** and **didanosine** are both nucleoside reverse transcriptase inhibitors (NRTIs); they act as analogues of natural substrates incorporated into viral DNA by reverse transcriptase and cause chain termination. This regimen targets multiple steps in the HIV replication cycle and has been investigated for its antiviral activity and tolerability. The combination is used orally and has demonstrated substantial reductions in viral load and improvements in CD4+ cell count in clinical studies of treatment-naive individuals with HIV[1].